Palisade Bio Announces Completion of Enrollment in LB1148 Dose Optimization Study
05. Juli 2023 08:45 ET
|
Palisade Bio, Inc.
Topline data expected in Q3 2023 Carlsbad, CA, July 05, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a biopharmaceutical company advancing therapies for acute...